Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
This important study, known as a Phase III trial, is looking at a new treatment called Sacituzumab Govitecan for people with advanced bladder cancer. This is cancer that has spread to other parts of the body (metastatic) or is too advanced to be removed by surgery (unresectable urothelial cancer). The study aims to compare Sacituzumab Govitecan with common treatments doctors usually choose for this type of cancer. Researchers will carefully check if Sacituzumab Govitecan helps people live longer, if their cancer shrinks, and how it affects their quality of life, including how they feel and their pain levels. They will also keep a close eye on any side effects to make sure the treatment is safe.
At a glance
What is this study about?
This clinical trial is designed to investigate a new treatment option, Sacituzumab Govitecan, for a specific type of advanced bladder cancer. This is cancer that has either spread to other areas of the body or has grown locally to a point where it can't be completely removed by surgery. Finding effective treatments for these advanced stages is crucial, and this study aims to see if this new medicine could be a better choice than what's currently available.
The main goal of the study is to find out if Sacituzumab Govitecan helps people live longer compared to standard treatments. Researchers will also be looking at other important aspects, such as how long people live without their cancer getting worse, whether the cancer shrinks or responds to the treatment, and how long any improvement lasts. They'll use advanced imaging techniques and expert reviews to assess these changes accurately.
Beyond just treating the cancer, this study also focuses on people's quality of life. The researchers will be asking participants about their physical well-being, their overall health, how much pain they might be experiencing, and how tired they feel. Understanding these effects is very important because a good treatment should not only fight the disease but also help people maintain the best possible quality of life.
Key takeaways
- This study is for advanced bladder cancer (urothelial cancer).
- It compares a new drug (Sacituzumab Govitecan) to standard treatments.
- The main goal is to see if the new drug helps people live longer.
- Researchers will also check for side effects and how treatments affect quality of life.
- You would receive regular treatments and check-ups if you join.
Who may be eligible?
To be considered for this study, you would need to be 18 years old or older. The study is open to both men and women.
Critically, you must have advanced bladder cancer that has either spread to other parts of your body or is locally advanced and cannot be removed by surgery. Your doctors would need to confirm this diagnosis.
There will be other medical checks and criteria that your doctor will discuss with you to make sure the study is a safe and appropriate option for your specific situation.
- Are you 18 years old or older?
- Have you been diagnosed with bladder cancer that has spread or can't be removed by surgery?
- Are you able to undertake regular hospital visits for treatment and check-ups?
- Are you able to provide informed consent (understand and agree to participate)?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would receive either the new medicine, Sacituzumab Govitecan, or one of the standard treatments typically used for your cancer. These treatments are given as an infusion, meaning they are put into your bloodstream, usually through a drip. The study is 'open-label,' which means both you and your doctor will know which treatment you are receiving.
You would have regular visits to the hospital for your treatment and to have various assessments. These assessments will include blood tests to check your general health and to look for any side effects. You would also have scans to see how your cancer is responding to the treatment. Additionally, you would fill out questionnaires asking about your pain, fatigue, and overall well-being.
After your main treatment period, there will be a follow-up period where doctors will continue to monitor your health and the progress of your cancer. The total length of your involvement in the study will depend on how your treatment progresses and is expected to last for several months, potentially longer, with ongoing check-ups.
Potential risks and benefits
Locations (8)
- —Italy
- —France
- —Sweden
- —Belgium
- —Greece
- —Ireland
- —Germany
- —Spain
Common questions
What kind of cancer is this study for?
This study is for advanced bladder cancer that has spread or can't be removed with surgery.
What is Sacituzumab Govitecan?
It's a new medicine being tested to see if it's better than current treatments for this type of cancer.
Will I know which treatment I'm getting?
Yes, this is an 'open-label' study, so you and your doctor will know which treatment you are receiving.
How long will I be in the study?
Your involvement will depend on your treatment progress, but it will involve regular visits and follow-ups over several months or longer.
Can I leave the study at any time?
Yes, you can choose to leave the study at any point without it affecting your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.